The molecular mechanism by which ATP-binding cassette transporter A1 (ABCA1) mediates cellular binding of apolipoprotein A-I (apoA1) and nascent high-density lipoprotein (HDL) assembly is not well understood.
H igh-density lipoprotein (HDL) plays a role in many cellular pathways via diverse mechanisms, including antithrombotic, vasoprotective, anti-inflammatory, and cholesterol efflux activities.
1,2 HDL assembly involves the cellular lipidation of extracellular apolipoprotein A-I (apoA1) by the membrane protein ATP-binding cassette transporter A1 (ABCA1). 3 The importance of the ABCA1 pathway in generating nascent HDL (nHDL) is demonstrated in human patients carrying mutations in ABCA1 (Tangier disease) who have extremely low levels of plasma HDL. 4 These patients have increased accumulation of cholesterol in peripheral tissues, resulting in premature atherosclerotic vascular disease. 5, 6 Although recent trials of HDL cholesterol-raising drugs have not appeared to prevent cardiovascular events, a consensus is building that it is HDL function in reverse cholesterol transport, rather than the levels of HDL cholesterol, that is protective against cardiovascular disease. 7, 8 For example, cholesterol efflux capacity of apolipoprotein B-depleted serum is inversely associated with both prevalent and incident cardiovascular disease, independent of HDL cholesterol levels. 7, 8 The mechanism of cellular lipidation of apoA1 by ABCA1 is not understood at the molecular level, with various models discussed in recent reviews.
9,10 ABCA1 has 2 well-established intermediate activities leading to apoA1 lipidation: (1) the outward translocation or flopping of phosphatidylserine (PS) to cell surface and (2) apoA1 binding to the cell surface. We recently characterized a third activity, the unfolding of N-terminal hairpin of apoA1 on the cell surface. 11 Interestingly, apoA1 binding to the cell surface is independent of the PS floppase activity of ABCA1 because the W590S-ABCA1 Tangier disease mutation is defective in PS floppase but not in apoA1 binding, whereas the C1477R-ABCA1 Tangier disease mutant is defective in apoA1 binding but not in PS floppase activity. [11] [12] [13] [14] It is important to note that both W590S and C1477R have impaired apoA1 lipidation, indicating that PS floppase and apoA1 cell surface binding are both required for efficient transfer of cellular lipids to apoA1 during nHDL biogenesis. 13 Several models have been proposed to explain the mechanism responsible for the specific binding of apoA1 to ABCA1-expressing cells: (1) apoA1 binding to cell surface PS because of ABCA1 PS floppase activity 15, 16 ; (2) direct interaction between apoA1 and ABCA1 as demonstrated by protein cross-linking 3, 17 ; (3) low-capacity binding of apoA1 to ABCA1 and high-capacity binding of apoA1 to membrane lipids 18, 19 ; and (4) apoA1 interaction with membrane protrusions because of ABCA1 bulk phospholipid outward translocase (floppase) activity. 20 Recent solid-phase binding studies from the Molday laboratory showed no direct binding between apoA1 and purified ABCA1 in the presence or absence of several classes of phospholipids, including PS. 21 Because these experiments were carried using immobilized ABCA1, the possibility of apoA1 and ABCA1 direct interaction on cell surface cannot be ruled out.
The major phospholipid constituents of HDL are phosphatidylcholine (PC), PS, phosphatidylethanolamine (PE), and phosphatidylinositol (PI). 22 Unlike other structural phospholipids, phosphatidylinositol phosphates (PIPs) are minor components of cellular membranes, but they serve as critical integral signaling molecules for multiple pathways. PI (4, 5) bis-phosphate (PIP2) is the major cellular PIP species, and it is predominantly found on the inner leaflet of the plasma membrane where it play roles in many cellular processes, such as membrane ruffling, endocytosis, exocytosis, protein trafficking, and receptor-mediated signaling. [23] [24] [25] [26] PIP2 binds to various effector proteins through interacting with pleckstrin homology (PH) domains, thereby regulating the cellular localization and activity of effector proteins. [27] [28] [29] PIP2 synthesis is tightly regulated by Pl kinases, such as PIP-5-phosphate 4 kinase (PIP5K), and PIP phosphatases, such as PTEN (phosphatase and tensin homolog deleted on chromosome 10). 26, 30 Here, we show that apoA1 binds to various PIPs, including PIP2, and that ABCA1 has PIP2 floppase activity independent of its PS floppase activity. ABCA1 increases cell surface PIP2, facilitating apoA1 binding and lipidation. Furthermore, PIP2 itself is effluxed to apoA1 during nHDL formation, and it is found on human and mouse HDL, where it can be delivered to target cells in a scavenger receptor-BI (SR-BI)-dependent manner. We propose a new model for apoA1-ABCA1-mediated HDL biogenesis, highlighting the essential role of PIP2 in this process.
Methods
A brief description of the methods is provided below. Detailed description of the materials and methods are available in the Online Data Supplement.
Protein-Lipid Overlay Assays
The PIP strip and sphingo strip membrane assays (Echelon Biosciences) were performed according to the manufacturer's protocol.
Surface Plasmon Resonance
Binding kinetics of PIP2 with different apolipoproteins was analyzed using a Biacore3000 instrument. Either biotinylated apoA1 or biotinylated PIP2 was immobilized on streptavidin sensor chips. For comparing binding kinetics of PIP2 with apoA1, apolipoprotein A-II (apoA2), and apolipoprotein E (apoE), these proteins were immobilized by covalent coupling on a CM5 sensor chip.
Fluorescence Anisotropy
Increasing concentrations of apoA1 were incubated with fatty acidlabeled bodipy PIP2 in a quartz cuvette at 25°C. Relative anisotropy was determined using polarized filters with excitation at 503 nm and emission at 513 nm in a Perkin Elmer spectrofluorimeter.
Liposome Clearance Assay
Multilamellar vesicles (MLV) were prepared from 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) with or without 5 mol% PIP2. These MLVs were incubated with human apoA1 at 25°C. MLV solubilization by human apoA1 was monitored by measuring sample turbidity (absorbance) at 325 nm. Liposome floatation assay was performed as described.
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ApoA1 Oligomerization
ApoA1 was incubated in the presence or absence of PIP2 or POPC at 1:4 mol ratio and then cross-linked by the addition of bis(sulfosuccinimidyl) suberate (BS3, Pierce) for 30 minutes at room temperature. Oligomerization was visualized by SDS-PAGE and apoA1 Western blot.
ABCA1 Induction and Cholesterol Efflux
ABCA1 induction in RAW264.7 cells by 0.3 mmol/L 8Br-cAMP and methods for cholesterol efflux were previously described.
32 ABCA1 was induced in stably transfected baby hamster kidney (BHK) cells by 16-to 24-hour incubation with 10 nmol/L mifepristone.
Inositol-Containing Lipid Efflux
Cells were labeled with 40 μCi/mL of [ 3 H]myo-inositol for 24 hours followed by ABCA1 induction in serum-free medium as indicated. The cells were washed and chased for 4 to 6 hours in serum-free medium in the presence or absence of 5 μg/mL apoA1. The chase media and cellular lipids were subjected to acidic solvent extraction, yielding the fraction containing PI and PIPs. Radioactivity was determined by scintillation counting for efflux calculations.
Nonstandard Abbreviations and Acronyms
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ATP-binding cassette transporter A1 
SR-BI-Mediated PIP2 Uptake
Mifepristone SR-BI-inducible BHK cells were treated with or without 10 nmol/L mifepristone for 14 hours. 34 Human HDL was labeled with [ 3 H]PIP2 and incubated at 100 μg/mL with cells in serum-free media for 4 hours at 37°C. Cellular lipids were extracted, and 3H was determined by scintillation counting and normalized to cellular protein.
Statistical Analyses
Data are shown as mean±SD. Comparisons of 2 groups were performed by a 2-tailed t test, and comparisons of ≥3 groups were performed by 1-way ANOVA with Bonferroni posttest. For these multiple comparison tests, all columns were compared against each other, and the letter above a bar shows significant difference versus all other columns marked with different letters. All statistics were performed using Prism software (GraphPad).
Results
Lipid-Free ApoA1 Binds to PIPs but Not to Other Major Phospholipids
ABCA1 is required for HDL biogenesis; it remodels the plasma membrane, translocating PS to the cell surface and promoting apoA1 binding. To determine the lipid-binding profile of lipid-free apoA1, lipid-protein overlay assays were performed using phospholipid/PIP and sphingolipid membrane strips. As PC is the major cellular and HDL phospholipid and previous studies implicated PS in apoA1 binding to the cell surface, we expected that apoA1 might bind to these lipid species. However, lipid-free apoA1 was directly bound only to PIPs containing 2 or 3 head-group phosphates and not to other lipids, including PC, PS, or PI ( Figure 1A ). ApoA1 did not bind to PI3P, PI4P, PI5P, or sphingosine 1-phosphate, indicating that mere presence of phosphate in the head group is not sufficient for apoA1 binding. Furthermore, lipid-free apoA1 did not bind to any lipids on the sphingolipid strip, including sphingomyelin, ceramide, and cholesterol (Online Figure I) . Thus, apoA1 binds specifically to PIP2 isoforms and PI (3, 4, 5) tris-phosphate. Because PI(4,5)P2 is a major cellular PIP2 species that is particularly enriched at the cell surface, we performed further experiments using this PIP2 species. Binding of apoA1 to immobilized PIP2 was demonstrated by surface plasmon resonance ( Figure 1B ). In addition, PIP2, but not PC, showed direct binding to immobilized apoA1 by surface plasmon resonance in dose-dependent manner ( Figure 1C ). To ensure that apoA1 binding to PIP2 was not artifactual as a result of its immobilization on a membrane, we performed apoA1-PIP2 solution-binding assays using fluorescence anisotropy, which demonstrated high-affinity binding of apoA1 to Bodipy fatty acid-labeled PIP2 (k d =93 nmol/L; Figure 1D ). To determine whether apoA1 can bind to PIP2 in a membrane environment, we performed a liposome floatation assay. We confirmed apoA1 binding to PIP2 (5 mol%) in POPC MLVs. We observed increased comigration of apoA1 with the PIP2 MLVs versus control MLVs in the top 0% sucrose gradient fraction ( Figure 1E ).
Other Amphipathic Apolipoproteins Bind PIP2
Many proteins bind PIP2 through their conserved PH domains 35 ; however, recent studies have shown that proteins lacking a PH domain can bind to PIP2 by adapting a cationic grip dimeric configuration that specifically accommodates the head group of PIP2. 36, 37 ApoA1 does not contain a PH domain, but its class A amphipathic helical structure contains a surface lined with positively charged lysine and arginine residues, which we postulate to be responsible for its PIP2-binding activity. In support of this hypothesis, we tested PIP2 binding to apoA2 and apoE, other ABCA1 acceptors with similar class A amphipathic helical structures. We immobilized apoA1, apoA2, and apoE to surface plasmon resonance membranes and found that PIP2 reversibly bound to each of these proteins, with K d values ranging from ≈60 nmol/L to 1.3 μM (Online Figure IIA- Figure IIA) , similar to the K d obtained by fluorescence anisotropy ( Figure 1D ).
PIP2 Promotes ApoA1 Monomer Formation and Lipid Solubilization
Lipid-free apoA1 exists in equilibrium between its monomeric and oligomeric forms, and the lipid-free monomer is postulated to mediate the initial interaction with the cell membrane and act as the primary ABCA1 acceptor. 38, 39 We hypothesized that PIP2 binding to apoA1 may promote apoA1 monomerization, leading to increased membrane insertion. We found that preincubating PIP2, but not PS, with lipid-free apoA1 shifted the equilibrium toward the monomeric form, as assessed by SDS-PAGE after addition of the chemical crosslinker BS3 (Figure 2A ). Thus, PIP2 both recruits apoA1 to the lipid surface and promotes its monomeric structure favored for lipid solubilization. To test the hypothesis that PIP2 can indeed promote apoA1-mediated lipid solubilization, we performed liposome
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clearance assays. Lipid-free apoA1 was added to DMPC MLVs with or without 5 mol% PIP2. The PIP2 containing MLVs were solubilized faster and to a greater extent than the DMPC-only MLVs ( Figure 2B ). POPC MLVs are resistant to apoA1 solubilization, but POPC:PS:cholesterol MLVs were previously found to be slowly solubilized by apoA1 at acidic pH. 40 Here, we found that the addition of 5% PIP2 to POPC:PS:cholesterol (70:20:10) MLVs increased the rate of their solubilization by lipid-free apoA1 at pH 5.0 ( Figure 2C ). Thus, in cell-free systems, the presence of PIP2 led to increased apoA1 monomerization, and liposome solubilization, which implies increased apoA1 insertion into the liposome membrane. 
ABCA1 Expression Exposes PIP2 at the Cell Surface
PIP2 is thought to be localized at the inner leaflet of the plasma membrane where it plays important roles in targeting proteins to the membrane, membrane trafficking, and signal transduction. 24, 26 PIP2 exposure on the cell surface would be required to interact with lipid-free apoA1, but cell surface PIP2 has not been previously described. Because ABCA1 has welldefined PS floppase activity, 16 we considered the possibility that ABCA1 might also act as a PIP2 floppase. Using a PI(4,5) P2-specific monoclonal antibody, we detected increased levels of cell surface PIP2 after induction of ABCA1 in RAW264.7 cells by 8Br-cAMP ( Figure 3A) . The enhanced level of cell surface PIP2 was decreased to the baseline level by treatment with exogenous phosphatidylinositol-specific phospholipase C (PI-PLC), without altering ABCA1 expression ( Figure 3A and 3B). To determine whether increased cell surface PIP2 was a cAMP effect independent of ABCA1, we knocked down ABCA1 expression using siRNA and observed that this treatment markedly decreased cell surface PIP2 levels and cholesterol efflux to apoA1 in 8Br-cAMP-treated RAW264.7 cells (Online Figure IIIA-IIIC) . To confirm the role of ABCA1 in translocating PIP2 to the cell surface, we stably transfected RAW264.7 cells with an intracellular PIP2-binding reporter protein (2X-PH-PLCδ-eGFP) that does not bind to other PIP species. 29 This reporter protein was localized mainly to the plasma membrane in RAW264.7 without ABCA1 induction, consistent with PIP2 localization in the inner leaflet of the membrane; however, on ABCA1 induction, the PIP2 reporter redistributed with increased cytosolic and less prominent plasma membrane localization ( Figure 3C ), which we attribute to PIP2 translocation to the outer leaflet of plasma membrane. We quantified the redistribution of this PIP2 reporter and found that its inner leaflet membrane association decreased from 42% to 27% on ABCA1 induction ( Figure  3D ; P<0.0001). All of these findings were independently reproduced in stably transfected BHK cells in which ABCA1 is inducible by mifepristone (Online Figure IVA-IVD) . Thus, in addition to ABCA1's well-known PS floppase activity, we demonstrated its PIP2 floppase activity, which both promote cell surface remodeling.
PIP2 and PS Floppase Activities of ABCA1 Are Independent of Each Other
The PS floppase and apoA1 cellular binding activities of ABCA1 can be distinguished from each other using naturally occurring Tangier disease-associated mutations in the first and second large extracellular domains of ABCA1. 5, 13 Cells expressing the W590S ABCA1 isoform are deficient in PS floppase activity but display normal apoA1-binding activity, whereas cells expressing the C1477R ABCA1 isoform have normal PS floppase activity but are deficient in apoA1 binding. [11] [12] [13] To evaluate if the PS and PIP2 floppase activities of ABCA1 are independent of each other, stably transfected human embryonic kidney (HEK)293 cells with equal expression of wild-type (WT)-ABCA1-GFP, W590S-ABCA1-GFP, or C1477R-ABCA1-GFP were analyzed for cholesterol efflux, cell surface exposure of PIP2 and PS, as well as apoA1 binding ( Figure 4A-4D ). Cells expressing WT ABCA1 had all of these activities induced versus control HEK293 cells. Cells expressing W590S-ABCA1 had defective cholesterol efflux and PS exposure, but had normal PIP2 exposure and apoA1 binding activity, whereas cells expressing C1477R-ABCA1 had defective cholesterol efflux, apoA1 binding, and PIP2 exposure, but had normal PS exposure. We were able to rescue the decreased cholesterol efflux activity of the C1477R-ABCA1-expressing HEK293 cells by enriching these cells with PIP2 via preincubation with MLVs containing POPC:PIP2 (90:10 mol ratio; Figure 4E ). Combining these results with earlier studies, we conclude that a specific mutation in first large extracellular domain of ABCA1 abrogates PS floppase activity, an activity that remodels the plasma membrane and increases cholesterol extractability, 14 whereas a specific mutation in the second large extracellular domain of ABCA1 abrogates PIP2 floppase activity, an activity that we show below is required for apoA1 binding. Thus, these 2 phospholipid floppase 
Cell Surface PIP2 Promotes ApoA1 Binding and Cholesterol Acceptor Activity
To probe the role of the ABCA1-mediated increase in cell surface PIP2, we determined the effect of a PI-PLC dose response treatment on apoA1 binding and cholesterol efflux. PI-PLC treatment of RAW264.7 and HEK293 cells greatly diminished ABCA1-dependent apoA1 binding and cholesterol efflux in a dose-dependent manner (Figure 5A and 5B; Online Figure  VA and VB). The limited cholesterol efflux activity of the PIP2 floppase competent W590S ABCA1 isoform was completely eliminated on treatment with PI-PLC in stably transfected HEK293 cells (Online Figure VC) . We blocked PIP2 exposure with an anti-PIP2 monoclonal antibody on ABCA1-induced RAW264.7 cells, and this also resulted in decreased apoA1 binding to the cell surface ( Figure 5C ), confirming that PIP2 plays a role in apoA1 binding. Preincubation of apoA1 with PIP2 decreased apoA1 binding and cholesterol efflux in ABCA1-induced RAW264.7 cells ( Figure 5C and 5D, with additional controls in Online Figure VI) . Thus, cell surface PIP2 is required for ABCA1-mediated apoA1 binding and cholesterol efflux. Furthermore, exogenous PIP2 added to lipid-free apoA1 appeared to compete against cell surface PIP2, diminishing apoA1 binding and cholesterol efflux. Instead of adding PIP2 to apoA1, when PIP2 was enriched on the cell membrane by treating RAW264.7 cells with POPC MLVs containing 10% PIP2, we observed increased apoA1 cellular binding in the absence of ABCA1 expression, but not to the extent seen in ABCA1-expressing cells ( Figure 5E ). POPC-only MLVs failed to induce apoA1 binding ( Figure 5E ). However, this liposomemediated cell enrichment with PIP2 failed to support cholesterol efflux in the absence of ABCA1 expression (Figure 5F ), indicating the requirement of ABCA1 for cellular lipid efflux activity, even in conditions where apoA1 binding is induced.
Alteration of Cellular PIP2 Metabolism Affects Cellular ApoA1 Binding and Cholesterol Efflux
To further demonstrate the central role of PIP2 in ABCA1-mediated apoA1 binding and cholesterol efflux, we performed siRNA knockdown of PIP5K, the enzyme that converts PI5P to PIP2. We found that the PIP5Kα isoform was highly expressed in both RAW264.7 and HEK293 cells and susceptible to protein knockdown by siRNA (Online Figure VIIA and VIIB), whereas the PIP5Kβ protein was not detected by Western blot. PIP5Kα knockdown significantly decreased ABCA1-mediated apoA1 binding and cholesterol efflux in both RAW264.7 and HEK293 cells (Figure 5G and 5H; Online Figure VIIC and VIID). We confirmed that PIP5Kα knockdown significantly decreased whole-cell PIP2 levels by 30% in RAW264.7 cells ( Figure 5I ). Conversely, we knocked down Tmem55b, a specific PIP2 phosphatase that converts PIP2 to PI5P and has a role in cellular cholesterol metabolism, 41 whose expression we detected in RAW264.7 cells (Online Figure VIIIA) . This knockdown modestly, but significantly, increased cellular apoA1 binding, cholesterol efflux to apoA1, and whole cell PIP2 levels (Online Figure  VIIIB-VIIID) . These gene knockdown studies support the central role of cellular PIP2 in ABCA1-mediated apoA1 binding and cholesterol efflux.
PIP2 Efflux to apoA1
To determine whether PIP2 could be effluxed from cells along with other phospholipids and cholesterol during HDL biogenesis, we labeled cells with [ 3 H]myo-inositol, and after chasing with apoA1, the conditioned media radioactivity in extracted lipids was measured. Efflux of inositol-labeled lipids was increased on ABCA1 induction in RAW264.7 cells ( Figure 6A) . However, the inositol lipid fraction can contain PI and other PIP species. Thus, we performed a protein-lipid overlay assay of lipids extracted from apoA1-containing conditioned media derived from cells with or without ABCA1 expression, and Figure 6B ). An ELISA assay was used to quantify the amount of PIP2 in the conditioned media. RAW264.7 cells expressing ABCA1 effluxed ≈20-fold more PIP2 to apoA1 versus control cells ( Figure 6C ). Similar results were observed for ABCA1-mediated inositol-labeled lipid efflux and PIP2 levels in the conditioned media in ABCA1-inducible BHK cells (Online Figure IXA and IXB) .
PIP2 Is Effluxed to ApoA1 In Vivo and Carried on HDL
To confirm the role of apoA1 as a PIP2 acceptor, we determined levels of PIP2 in fresh mouse plasma. Plasma from apoA1 knockout (A1 KO), WT, and human apoA1 transgenic 3 H]inositol-labeled lipids to apoA1 from RAW264.7 cells (mean±SD; ***P<0.001, by 2-tailed t test, n=3). B, PIP2 and PI4P in lipids from RAW264.7 cells and in apoA1-containing conditioned media visualized by lipid-protein overlay assays using tagged PIP2 or PI4P binding proteins. C, ABCA1-dependent efflux of PIP2 to apoA1 in conditioned media assessed by ELISA, normalized to cell protein (mean±SD; ***P<0.001, by 2-tailed t test, n=3).
mice contained apoA1-gene dosage-dependent levels of both cholesterol and PIP2, with 64-fold higher PIP2 levels in the human apoA1 transgenic versus A1 KO mice ( Figure 7A ). WT mice had plasma levels of ≈0.4 μM PIP2. The low level of plasma PIP2 in A1 KO plasma (≈0.03 μM) implies that most PIP2 is carried on HDL and not bound with albumin or found free in plasma. To determine whether PIP2 can be reverse transported from macrophages to the plasma, we performed a modified reverse cholesterol transport study, where macrophages were labeled in culture with [ 3 H]myo-inositol and implanted subcutaneously into A1 KO and WT mice. Plasma was collected 3 days post implantation, and radioactivity in PIP2 was determined after pull-down with a tagged PIP2-binding protein. Approximately 3-fold more of the injected radioactivity in PIP2 was recovered in the plasma of the WT hosts versus the A1 KO hosts (Figure 7B; P<0.01) . Thus, similar to cell-based assays, PIP2 can be effluxed to apoA1 in vivo.
FPLC separation of fresh human plasma determined that almost all of the PIP2 was found in the HDL fractions ( Figure 7C ). In human HDL, 2 PIP2 species were detected by liquid chromatography tandem mass spectrometry, consistent with either 18:0, 20:4 fatty acids or 16:0, 20:4 fatty acids ( Figure 7D ). Therefore, PIP2 is effluxed from cells and is carried on HDL, implying that HDL may serve as a vehicle to deliver PIP2 to target tissues. We labeled HDL with [ 
Discussion
Several models have been proposed for the mechanism by which apoA1 binds to ABCA1-expressing cells to initiate nHDL assembly. 2, 9, 10 Here we demonstrated that ABCA1 is a PIP2 floppase leading to increased cell surface PIP2 and redistributing a cellular PIP2 reporter away from the inner leaflet of the plasma membrane. We then demonstrated using several independent lines of evidence that apoA1 binding to ABCA1-expressing cells and efflux to apoA1 is mediated by PIP2: (1) apoA1 preincubation with PIP2 diminished cellular apoA1 binding and cholesterol efflux presumably because of competition with cell surface PIP2; (2) direct addition of PIP2-containing liposomes could rescue the cholesterol efflux activity of HEK293 cells expressing the C1477R ABCA1 isoform that is deficient in PIP2 floppase activity; (3) direct addition of PIP2-containing liposomes to RAW264.7 cells could promote apoA1 cellular binding, but not cholesterol efflux, in the absence of ABCA1 expression; (4) treatment of RAW264.7 or HEK cells with PI-PLC decreased cell surface PIP2, apoA1 binding, and cholesterol efflux; (5) knockdown of PIP5Kα, a PIP2 synthesizing enzyme, led to reduced cellular PIP2 levels, apoA1 binding, and cholesterol efflux; and (6) knockdown of Tmem55b, a PIP2 degrading enzyme, led to increased cellular PIP2 levels, apoA1 binding, and cholesterol efflux. Because ABCA1 flops PIP2, the PIP2 levels will be highest in proximity to ABCA1, and PIP2 may serve as a bridge to account for the previously observed specificity of apoA1 crosslinked to ABCA1. 3, 12, 19 Reboul et al purified ABCA1 and did not observe apoA1 binding in the absence or presence of PC and PE. However, because PIP2 was not used in their studies, they could not assess if PIP2 could serve as bridge between ABCA1 and apoA1. Quazi et al 42 assessed the floppase activity of liposome-reconstituted ABCA1 using several different phospholipid substrates, and they observed ABCA1 floppase of PC, PS, and SM, but not PE or phosphatidylglycerol. PIP2 floppase activity was not assessed in their study.
We now propose a revised model for the ABCA1-mediated biogenesis of nHDL that incorporates the role of PIP2 in this process (Figure 8 ). The PS floppase activity, disrupted by mutations in the first large extracellular domain of ABCA1, promotes membrane remodeling that makes the membrane more susceptible to detergents, such as sodium taurocholate, or amphipathic proteins, such as apoA1. 12, 13, 15, 16 The PIP2 floppase activity, disrupted by mutations in the second large extracellular domain of ABCA1, promotes apoA1 binding to the cell surface. Once bound to the cell, the PIP2-apoA1 interaction may favor apoA1 monomerization, which may promote our previously observed partial unfolding of the apoA1 N-terminal helical hairpin on the cell surface. 11 Gursky et al 39 recently proposed that N-terminalunfolded apoA1 can redimerize through domain swapping around repeat 5 acquiring the conformation that can insert into the cell membrane, microsolubilize cellular lipids, and assemble nHDL particles that are released from the cell. We suspect that the unfolded apoA1 on the cell surface may be able to form dimers, trimers, or tetramers in the conformation that allows membrane insertion and microsolubilization, resulting in the release of several distinct size classes of nHDL, as previously observed by Mulya et al. 43 Nagata et al 44 showed that ABCA1 forms immobile dimers on the plasma membrane, which are dissociated into monomers after apoA1 addition. Our model is compatible with ABCA1 dimers serving as the active PIP2 floppase and the suggestion by Nagata et al that apoA1 dimers (we suggest these are in the unfolded N-terminal confirmation) interact with ABCA1 dimers. 44 Thus, membrane lipid remodeling by ABCA1 flops both PS and PIP2 to the cell surface, and both of these activities are required for maximal cholesterol efflux.
PIP2, found prevalently on the inner leaflet of the plasma membrane, plays a role in protein targeting and many aspects of cell biology. Several actin-binding proteins bind to PIP2, which promotes actin polymerization and actin-membrane linkages. 23 In addition, increasing cellular PIP2 leads to increased recruitment of the endocytic adaptor protein AP-2 to the plasma membrane and increased rates of receptormediated endocytosis. 27 In fact, the observation that ABCA1-defective Tangier disease fibroblasts have increased rates of receptor-mediated endocytosis can now be interpreted in light of ABCA1's PIP2 floppase activity, such that defective ABCA1 may increase PIP2 in inner leaflet, resulting in increased endocytic vesicle formation. 45 ABCA1 deficiency in macrophages is associated with free cholesterol accumulation and increased expression of inflammatory genes in response to toll-like receptor (TLR) ligands. 46 This appears to be mediated by an ABCA1-dependent depletion of lipid-raft cholesterol that inhibits the trafficking of Myd88-associated TLRs to the plasma membrane. 47 The anti-inflammatory effects of LXR (liver X receptor) agonists in macrophages are mediated by the ABCA1 action on Myd88, TRAF6, and TLR recruitment. 48 In addition to ABCA1's cholesterol-mediated lipid raft remodeling, the PIP2 floppase activity of ABCA1 may also play a role in TLR trafficking. Kagan and Medzhitov demonstrated that the PIP2-binding adaptor TIRAP recruits MyD88 and TLR to the plasma membrane to initiate TLR signaling. 49 Thus, the ABCA1-mediated flop of PIP2 out of the inner leaflet would be expected to decrease TLR trafficking to the plasma membrane, consistent with the observed effects of ABCA1 expression. In addition, ABCA1 may play an important role in AKT signaling, as Landry et al demonstrated that ABCA1 expression decreased lipid-raft cholesterol and inhibited EGF-mediated AKT phopshorylation. 50 AKT phosphorylation is dependent on PI(3,4,5)tris-phosphate, which is generated via phosphorylation of PIP2. We can now reinterpret the ABCA1 inhibition of AKT phosphorylation in light of the ABCA1 PIP2 floppase activity, which would decrease the substrate for PI (3, 4, 5) tris-phosphate generation.
We demonstrated here that apoA1, apoA2, and apoE can all bind to PIP2 (Online Figure II) , with apoA1 binding with a K d =100 nmol/L ( Figure 1E ). None of these proteins have a consensus PH domain associated with PIP binding; however, other domains, including the PX (phosphoinositide-binding structural domain) domain of a PI3-kinase, the ENTH (Epsin N-terminal homology) domain of Epsin, the ANTH (AP180 N-terminal homology) domain of AP180, the TRAF (TNF receptor-associated factor) domain of TRAF6, and the dimeric cationic grip domain of tomato defensin TPP3 (tomato pistil predominant 3), also bind to PIP2. 36, 51, 52 The common feature of PIP2-binding proteins is the coordination of PIP head-group phosphates by positively charged amino acid residues. The class A amphipathic helical secondary structure of apoA1, apoA2, and apoE all contain a positively charged surface adjacent to the hydrophobic surface, 53 and we postulate that the tertiary structure of these apolipoproteins, along with short synthetic class A amphipathic helical peptides, can effectively coordinate PIPs through their positively charged residues. The PIP binding property of class A amphipathic helical peptide would not demonstrate stereospecificity, and this could explain why these peptides made entirely of D-amino acids function efficiently as ABCA1-depedent cholesterol acceptors. 54, 55 As apoA1 is the most abundant apolipoprotein in plasma with normal levels of 1 to 2 mg/mL, any weak detergent activity of apoA1 could be detrimental to the host. We speculate that the ABCA1 PIP2 floppase activity may have coevolved with the PIP2-binding activity of apoA1 and other amphipathic apolipoproteins as a mechanism to prevent the promiscuous detergent activity of these proteins, allowing apoA1 to solubilize lipids from cells under tight control by ABCA1 expression.
Our finding that PIP2 is effluxed by ABCA1 to nHDL and then circulates in the plasma on HDL has implications for the pleiotropic activity of HDL. HDL carries a wide array of signaling molecules, including sphingosine 1-phosphate, which is carried on ApoM containing HDL and plays many biological roles.
56 PIP2 carried on circulating HDL might also serve as a signaling molecule by the delivery of PIP2 to target cells via SR-BI. In WT mice, we observed plasma PIP2 levels at ≈0.4 μmol/L; however, with plasma apoA1 of ≈ 32 μmol/L, 57 and assuming on average 2.5 apoA1 molecules per HDL, the final HDL concentration is ≈13 μmol/L. Thus, it seems that there is <1 PIP2 molecule per HDL particle in circulation. This may be because of PIP2 uptake by cells via SR-BI (as shown) or other pathways, PIP2 degradation in the circulation, or a PIP2 under estimate because of loss during lipid extraction.
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What New Information Does This Article Contribute?
• ApoA1 binds tightly and specifically to phosphatidylinositol (4.5) bisphosphate (PIP2).
• ABCA1 transfers PIP2 from the inner to the outer leaflet of the plasma membrane, and this is required for the ABCA1-mediated induction of cellular binding of apoA1.
• PIP2 is effluxed along with cholesterol from ABCA1-expressing cells to nascent HDL, and PIP2 is found on circulating HDL.
The molecular mechanism by which ABCA1 assembles exogenous apoA1 into nascent HDL is not known. This article demonstrates for the first time that apoA1 binds specifically to the phospholipid PIP2. This was followed by the discovery that ABCA1 has PIP2 floppase (outward translocase) activity independent of its well-defined PS floppase activity, leading to PIP2 exposure on cell surface. PIP2 has not previously been characterized on the cell surface. Cell surface PIP2 serves as ligand for apoA1 to mediate apoA1 binding to ABCA1-expressing cells, and this cell surface PIP2 promotes cholesterol efflux to apoA1. PIP2 itself is effluxed to apoA1 from ABCA1-expressing cells, and this is the first demonstration that PIP2 is found on plasma HDL in mice and humans. This HDL-associated PIP2 can be taken up by target cells expressing the HDL receptor scavenger receptor-BI. We suggest a new model for the mechanism of ABCA1-mediated lipidation of apoA1 in the assembly of nascent HDL, which incorporates the PIP2 floppase activity of ABCA1, as well as apoA1 conformational changes. It was not clear if lipid-poor apoA1 binds directly to ABCA1 or to membrane lipids. Our data suggests that apoA1 binds directly to PIP2 in the membrane lipids.
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Supplemental Materials Detailed Methods
Materials: PIP strips (P-6001), Sphingo strips (S-6000), PI(4,5)P2 (P-4524), PI(4,5)P2 ELISA kit (K-4500), PI(4)P Grip (G0402), PI(4,5)P2 Grip (G4501), biotin-PIP2 (C-45B6), fatty acid labeledbodipy PIP2 (C-45F16a ), and FITC conjugated Anti-PIP2 antibody(Z-G045) were from Echelon Biosciences. HRP-conjugated GST antibody was from Sigma. Alexa647-Antibody labeling kit was from Molecular Probes (Cat No. A-20186). Purified recombinant human proteins apoA2 (TP721104) and apoE (TP723016) were from Origene. [
3 H]-labeled PIP2 (NET895005UC), myo-inositol (NET1177001MC), and cholesterol (NET13900) were from Perkin Elmer. ApoA1 was purified form human plasma 1 , and dialyzed against PBS. Recombinant human apoA1 and truncation mutations were prepared as previously described.
2 RAW264.7 cells were from ATCC. Mifepristone ABCA1-inducible BHK cells, as previously described were obtained from Chongren Tang, University of Washington.
3 Mifepristone SR-BI-inducible BHK cells, as previously described 34 , were obtained from Alan Remaley, NIH.
4 ABCA1-GFP and the mutant isoform stably transfected HEK cells were as previously described. 
Protein-lipid overlay assays:
The PIP strip and sphingo strip membranes were blocked with 5% milk powder in PBS-Tween for 30 min, and apoA1 was added at 50 μg/ml and incubated at room temperature for 2 hr. The bound protein was detected by using anti human apoA1 goat (Meridian Life Science, #K45252G) antibody and HRP conjugated anti-goat antibody. HRP was visualized using ECL reagent (Pierce) and exposure to x-ray film. Lipids extracted from conditioned media or cells were dissolved in methanol:chloroform:12N HCl (40:80:1) and spotted onto nitrocellulose membranes. After treating with casein blocker (Thermo scientific; #37528), the membranes were incubated with GST-PLCδ-PH (1μg/ml, Echelon Biosciences) to detect PIP2, or with GST-SiDC-3C (1μg/ml, Echelon Biosciences) to detect PI4P. The binding interactions were detected using HRP-conjugated anti-GST antibody (Sigma) and ECL chemiluminescence.
Surface Plasmon resonance: Binding kinetics of PIP2 with different apolipoproteins was analyzed using a Biacore3000 instrument. Either biotinylated apoA1 or biotinylated PIP2 was immobilized on a streptavidin sensor chip (GE Healthcare ). The immobilized apoA1 or PIP2 was stable over the course of the experiment and baseline drift was <10 response units (RU)/h after the washing with Hepes buffered saline (HBS) buffer. Different concentrations of apoA1 or PIP2 were injected using the KINJECT procedure at flow-rate of 10 μl/min and dissociation was monitored by injecting HBS buffer. The injections were performed in triplicate for each ligand concentration. For comparing binding kinetics of PIP2 with apoA1, apoA2 and apoE, these proteins were immobilized by covalent coupling on a CM5 sensor chip (GE Healthcare) using EDC-NHS reagents. PIP2 was injected as described above. Corrected response data were fitted with BIAevaluation software version 4.01, and K d values were calculated. expressing RAW264.7 cells ± exogenous PIP2 pre-incubated with apoA1 prior to adding to cells (PIP2:apoA1, 5:1 mole ratio), or ± PIP2 specific monoclonal antibody (2 μg/ml, PIP2 antibody was added to cells along with apoA1). Cells without ABCA1 expression were used as control. B. Cholesterol efflux from control and ABCA1-expressing RAW264.7 cells to apoA1 (5 μg/ml) that was pre-incubated ± exogenous PIP2 (PIP2:apoA1, 5:1mole ratio). For both panels, mean ± SD; different letters show p<0.01 by ANOVA Bonferroni posttest, n=3. GAPDH was used as loading control. Cells were treated with siRNAs for 72 hr, protein extracts were prepared and resolved on SDS gels, followed by western blot analysis and probing with anti-PIP5K or GAPDH antibodies. Cholesterol efflux assays (C) and apoA1 binding assays (D) were performed in HEK293 cells and ABCA1 stably transfected HEK293 cells treated with either scrambled siRNA or siRNA against PIP5K. Cholesterol efflux activity was determined via radioactive cholesterol labeling followed by apoA1 chase and apoA1 binding was determined via flow-cytometry.
Online Fig VIII:
TMEM55b alpha knockdown increased apoA1 cell surface binding and cholesterol efflux: A. Levels of Tmem55b in RAW264.7 cells treated with either scrambled siRNA or siRNA against Tmem55b. GAPDH was used as loading control. RAW cells were treated with siRNAs for 72 hr, protein extracts were prepared and resolved on SDS gel, followed by western blot analysis and probing with anti-Tmem55b or GAPDH antibodies. RAW cells treated with either scrambled or siRNA against Tmem55b and apoA1 binding (B), cholesterol efflux (C), and PIP2 levels (D) were assessed. Mean ± SD, n=3; for panel B different letters show p<0.001 by ANOVA Bonferroni posttest,
